Table 1 Baseline and clinical characteristics of the participants

 Age (years)

57.74 ± 8.48

58.98 ± 9.32

0.214

 Male

116

141

0.120

 Hypertension (%)

6

125

< 0.001

 Diabetes mellitus (%)

2

46

< 0.001

 hyperlipidemia (%)

0

32

< 0.001

 TC (mmol/L)

4.81 ± 0.94

3.75 ± 1.06

< 0.001

 TG (mmol/L)

1.26 (0.82, 1.48)

1.59 (0.79, 2.04)

< 0.001

 HDL-C (mmol/L)

1.41 ± 0.33

1.01 ± 0.26

< 0.001

 LDL-C (mmol/L)

2.27 ± 0.586

1.91 ± 0.70

< 0.001

 Apo-A1 (g/L)

1.62 ± 0.21

1.48 ± 0.28

< 0.001

 Apo-B (g/L)

0.91 ± 0.20

0.82 ± 0.24

< 0.001

 LP(a) (mg/L)

78.20(16.79, 120.33)

115.84(33.29,184.10)

< 0.001

 AST (IU/L)

25.14 (20.00, 29.17)

30 (17.75,35.25)

0.003

 CK-MB (IU/L)

8.43 ± 6.90

15.85 ± 101.90

< 0.001

 LDH (IU/L)

187.43 ± 42.60

193.49 ± 66.17

0.272

 HBDH (IU/L)

119.69 ± 30.05

128.19 ± 51.66

0.042

 hs-CRP (mg/L)

5.26 (2.17, 5.71)

7.00 (4.75, 12.33)

< 0.001

 HCY (μmol/L)

11.30 (8.90,12.50)

11.2 (8.07, 13.40)

0.012

 CysC (mg/L)

0.59 ± 0.14

0.60 ± 0.21

0.445

 GSP (mmol/L)

2.61(2.46, 2.74)

2.62(2.39, 2.89)

0.086

SREBP-1 (fold change)

1.00 ± 1.17

0.66 ± 1.14

0.005

SREBP-2 (fold change)

1.00 ± 0.90

0.93 ± 1.34

0.528

Statins Medication

0

69

< 0.001